Navigation Links
Hormone therapy for prostate cancer does not appear to increase cardiac deaths

Treating prostate cancer patients with drugs that block hormonal activity does not appear to increase the risk of death from cardiovascular disease, according to a study led by Massachusetts General Hospital (MGH) researchers. While a 2006 report from members of the same study team found that treatment with gonadotropin-releasing hormone (GnRH) agonists increased the risk of diabetes and heart disease, the current study is the first to examine whether treatment actually increased heart-disease-related deaths. In their Journal of Clinical Oncology report, which has been released online, the researchers note that GnRH agonist treatment has a number of adverse side effects, which should be kept in mind when determining treatment strategies.

"Hormonal therapy for prostate cancer has become routine for many patients, so it's even more important to understand the potential adverse effects of treatment," says lead author Jason Efstathiou, MD, PhD, of the MGH Cancer Center. "Given recent concerns about the safety and impact on cardiac health of hormonal therapies particularly GnRN agonists our study is quite timely."

Since the male hormones called androgens can accelerate the development of prostate cancer, reducing their activity is a standard part of treating the disease. Most commonly this is done with GnRH agonists that block the production of all sex hormones. GnRH agonist therapy is routinely administered to men whose cancer has spread beyond the prostate gland, and its use in patients whose tumors appear confined to the prostate is becoming more common. It is estimated that one-third of the two million prostate cancer survivors in the U.S. are currently receiving this therapy, making understanding the potential adverse effects of treatment particularly important.

The earlier report from a Harvard Medical School team including Matthew Smith, MD, PhD, of the MGH Cancer Center, who is corresponding author of the current study found that men with localized prostate cancer who received GnRH agonist therapy had a greater risk of developing diabetes or cardiovascular disease than patients not receiving hormonal treatment. To specifically investigate the relationship between GnRH agonist therapy and death from cardiovascular disease, the current study analyzed data from a 1987-92 clinical trial in which almost 1,000 patients were treated for locally advanced prostate cancer with either the GnRH agonist goserelin plus radiation therapy or radiation therapy alone.

During the decade following completion of the clinical trial, more than half the participants died from various causes. Of the 574 deaths, 117 were from cardiovascular disease, but whether or not patients had received the GnRH agonist apparently had no effect on the risk of cardiovascular death. Instead, it was established cardiac risk factors including heart disease or diabetes that existed prior to GnRH agonist treatment that appeared to increase the risk of dying from cardiovascular disease.

"The absence of an increase in cardiovascular mortality does not exclude the possibility that GnRH agonists increase non-cancer deaths through other mechanisms," Efstathiou stresses. "In addition to the increased risk for diabetes identified in the 2006 study, we know they can raise the risk of fractures and anemia both of which can reduce survival and can have adverse effects on weight gain, cholesterol levels, mood and sexual function.

"While our study supports the continued use of GnRH agonists in situations where the benefit for cancer control has been established typically the treatment of advanced or more aggressive prostate cancer clinicians should keep in mind the risks of diabetes and cardiovascular disease and help their patients adopt strategies to reduce those risks," he adds. "Further studies are needed to evaluate potential risks for men with earlier stage prostate cancer, for whom the role of GnRH agonists is not as well defined, and treatment decisions need to carefully weigh potential risks and benefits." Efstathiou is an instructor in Radiation Oncology at Harvard Medical School.


Contact: Katie Marquedant
Massachusetts General Hospital

Related medicine news :

1. Drop in breast cancer incidence linked to hormone use, not mammograms
2. Researchers develop long-lasting growth hormone
3. One of the Largest Post-WHI Physician Surveys Shows More Education is Needed: Patient Misinformation About Hormone Therapy Remains High
4. Less than one-third of women aware of landmark hormone therapy study, Stanford researcher finds
5. Most Women Unaware of Hormone Replacement Study
6. Survival data presented from phase II study of hormone-resistant prostate cancer patients
7. Hormone May Play Key Part in Creating Memories
8. Hormone Therapy for Prostate Cancer Linked to Heart Risks
9. Wyeth to Appeal Nevada Hormone Therapy Trial Verdict
10. New data on hormone therapy must lead to re-evaluation of official guidelines
11. From Hot Flashes to Breast Cancer: ZRT Labs Hormone Testing Catches On As Women Consider Safer, More Natural Options.
Post Your Comments:
(Date:11/27/2015)... ... 2015 , ... CBD College is proud to announce that on ... accreditation to its Diagnostic Medical Sonography program. CBD College is honored to join this ... colleges and universities in the state of California make the cut. CBD College is ...
(Date:11/27/2015)... San Francisco, California (PRWEB) , ... November 27, 2015 , ... ... 1969 Janis Joplin Ann Arbor Michigan boxing style concert posters. This is one of ... 1969 at the Canterbury House at the University of Michigan in Ann Arbor. The ...
(Date:11/26/2015)... ... November 26, 2015 , ... Inevitably when people think Thanksgiving, they also think ... during the Black Friday and Cyber Monday massage chair sales to receive ... high and low to find the best massage chair deals, they can see all ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... of workshops to discuss bioavailability and the need to integrate dose form selection ... in collaboration with OBN, the membership organization supporting and bringing together the UK’s ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... opinion process, participated in the 61st annual Employee Benefits Conference. The Employee Benefits ... place Sunday, November 8th through Wednesday, November 11th, 2015. The conference was held ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... STOCKHOLM , November 26, 2015 ... the potential to use SyMRI to find optimal contrast weighting ... brain tumor metastases, and has signed a research agreement with ... at the hospital. Using SyMRI, it is possible to generate ... parameter settings after the patient has left, thus making it ...
(Date:11/26/2015)... ) has ... Future Horizons and Growth Strategies in the ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> ) has announced the ... and Growth Strategies in the French Drugs ...
(Date:11/26/2015)... Research and Markets ( ) has announced the ... Type (Dressings, Therapy Devices, Active Wound Care), Application (Surgical ... Geography - Global Forecast to 2020" report to ... --> The purpose of this report is to ... advanced wound care market. It involves deep dive analysis ...
Breaking Medicine Technology: